Hypereosinophilic Syndromes (HES) : from diagnosis to management

Webconférence exceptionnelle du 14 mai 2026 Hypereosinophilic Syndromes (HES) : from diagnosis to management, by Dr Matthieu GROH (Internal Medecine, Hôpital Foch, Suresnes, Reference Center for Hypereosinophilic Syndromes). This webconference is also available in french : In this webconference : 00:47 Underlying mechanisms driving hypereosinophilia 02:13 HES : what are we talking about ? 03:54 Wide diversity of clinical manifestations 04:47 Skin involvement 05:20 Eosiniphilic pneumoniae 06:07 GI-tract involvement 06:39 Cardiac involvement 07:26 Eosinophilia-associated coronary vasospasm 08:45 Eosinophil-induced vascular manifestations 09:12 Eosinophilic vasculitis ? 10:24 Epidemiology 11:33 M/LLN-eo with FIP1L1 : PDGFRA 13:34 Other M/LN-eo and TK gene fusions 14:04 JAK/STAT-mutated HES 15:35 JAK/STAT-mutated HES : mutational status and OS 15:52 JAK/STAT-mutated HES : predictors of mortality 16:23 3-4+ lymphotic HES : and indolent T-cell lymphoma 16:45 3-4+ lymphocytic HES : clinical spectrum 17:11 ANCA status correlates with EGPA phenotype 17:48 Similarities between ANCA-neg EGPA and I-HES 18:17 IgG4-Related Disease "with eosinophilia" 19:46 Treatment : general principles 20:44 Treatment : HEus 21:16 Treatment : idiopathic HES 22:56 Mepolizumab for HSE : episode #1 24:29 Mepolizumab for HSE : episode #2 25:32 When (and how) to use mepolizumab in HES ? 26:50 L-HES : a "blind spot" of mepolizumab 28:09 L-HES : JAKi and/or T-cell targeted therapies ? 30:04 Treatment : clonal HES More information on our website : https://www.fai2r.org/videotheque-par... Filière de santé des maladies auto-immunes et auto-inflammatoires rares Site : https://www.fai2r.org Facebook : / fai2r Instagram : / filiere_fai2r Twitter : / contactfai2r LinkedIN : https://www.linkedin.fr/company/fai2r